title: Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin.
abstract: BACKGROUND
  The authors examined the correlation between the expression of glutathione S-transferase-pi (GST pi) and the sensitivity of gastric cancer to anticancer agents.
  
  
  METHODS
  In 62 human gastric carcinomas, the expression of GST pi was immunohistochemically evaluated, and sensitivity to the anticancer drugs, cisplatin (CDDP), doxorubicin (DXR) aclacinomycin A (aclarubicin), (ACR), 5-fluorouracil (5-FU), mitomycin C (MMC) and carboquone (carbazilquinon) (CQ) was examined using the in vitro succinate dehydrogenase inhibition test. The authors used the Chinese hamster ovary (CHO) cell line and its variant CDDP-resistant cell line C/CDP-2, and they analyzed the relationship among CDDP-sensitivity, mRNA expression, and immunohistochemical staining.
  
  
  RESULTS
  Immunohistochemically detected GST-pi-positive tumors were noted in 35 of 62 excised tumors. There was no significant correlation between GST-pi expression and clinicopathologic features or prognosis. The succinate dehydrogenase activity of each drug for tumors, with regard to negative or positive GST-pi, was 34.9 plus or minus 13.7% and 46.0 plus or minus 22.0% for CDDP, with a significant statistical difference (P < 0.05). However, there was no statistical difference for the other drugs tested. C/CDP-2 cells showed a lower sensitivity to CDDP, a higher expression of mRNA for GST pi and a stronger immunohistochemical staining than CHO cells.
  
  
  CONCLUSIONS
  The overexpression of GST-pi is significantly related to the sensitivity of gastric cancer to CDDP.
authors.affiliation: Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Okuyama
authors.forename: Y
authors.initials: Y
authors.lastname: Maehara
authors.forename: K
authors.initials: K
authors.lastname: Endo
authors.forename: H
authors.initials: H
authors.lastname: Baba
authors.forename: Y
authors.initials: Y
authors.lastname: Adachi
authors.forename: M
authors.initials: M
authors.lastname: Kuwano
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D015250:Aclarubicin / Q000494:pharmacology; D000818:Animals; D016466:CHO Cells; D002225:Carbazilquinone / Q000494:pharmacology; D002277:Carcinoma / Q000201:enzymology* / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D002467:Cell Nucleus / Q000201:enzymology / Q000648:ultrastructure; D002945:Cisplatin / Q000494:pharmacology*; D006224:Cricetinae; D003593:Cytoplasm / Q000201:enzymology / Q000648:ultrastructure; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic; D005982:Glutathione Transferase / Q000032:analysis / Q000235:genetics*; D006801:Humans; D007527:Isoenzymes / Q000032:analysis / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000494:pharmacology; D011379:Prognosis; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D013274:Stomach Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D013385:Succinate Dehydrogenase / Q000037:antagonists & inhibitors; D015996:Survival Rate
chemical_list: D007527:Isoenzymes; D012333:RNA, Messenger; D002225:Carbazilquinone; D016685:Mitomycin; D015250:Aclarubicin; D004317:Doxorubicin; D013385:Succinate Dehydrogenase; D005982:Glutathione Transferase; D002945:Cisplatin; D005472:Fluorouracil